title: Visual acuity following intravitreal bevacizumab for macular edema associated with retinal vein occlusion.
abstract: OBJECTIVE
  To study prognostic factors for visual acuity (VA) after intravitreal bevacizumab injection (IVB) for macular edema (ME) associated with retinal vein occlusion (RVO), by evaluating the correlation between the final VA and VA at baseline and at 1, 3, and 6 months after the initial IVB.
  
  
  METHODS
  We studied retrospectively 79 eyes of 79 patients with ME secondary to RVO treated with IVB. The correlation between the final VA and VA at each visit was studied by using Pearson's correlation coefficient.
  
  
  RESULTS
  Baseline VA was significantly correlated with the final VA (r = 0.552, P < 0.0001). Postoperative VA at 1, 3, and 6 months after the initial IVB, however, was even more closely correlated with the final VA (r = 0.793, 0.816, 0.893, respectively; P < 0.0001 in each case). Additionally, eyes with a VA of 20/40 or better at 1 month achieved a significantly better final VA than did eyes with a VA worse than 20/40 at 1 month (P < 0.0001). This tendency was seen also in each RVO subgroup.
  
  
  CONCLUSIONS
  Although the baseline VA was significantly correlated with the final VA, postoperative VA was correlated even more closely with the final VA. VA shortly after the initial IVB seemed to reliably predict final visual outcome.
authors.affiliation: Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto, 606-8507, Japan.
authors.forename: Masafumi
authors.initials: M
authors.lastname: Ota
authors.forename: Akitaka
authors.initials: A
authors.lastname: Tsujikawa
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Miyamoto
authors.forename: Atsushi
authors.initials: A
authors.lastname: Sakamoto
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Murakami
authors.forename: Nagahisa
authors.initials: N
authors.lastname: Yoshimura
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012170:Retinal Vein Occlusion / Q000150:complications / Q000188:drug therapy*; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab